Falling interest rates may offer some support but acquirers are wary of policy changes here and abroad
Amryt Pharma
Flotation of Irish-run company could take place as soon as March
Deal volumes in the Republic were down in 2023 but in value terms were up nearly 600 per cent year on year, according to EY analysis
Value of M&A transactions fell 58% to €5.2bn in first half, says William Fry
US funds make $79m profit on investment in Irish rare disease drug developer, and could yet make another $62.5m
Irish pharma company secures a 100%-plus premium for shareholders in deal to sell the business to bigger Italian rival
Eight-year old Amryt got EU approval last year for first treatment for rare genetic condition known as butterfly skin disease that primarily affects children
Drug firm says says delisting would enhance liquidity of trading
Rare disease specialist says performance was ‘strong’ in ‘extremely busy’ period
US Food and Drug Administration’s priority review can expedite review process to six months
Rolling submission began last summer
Placing of shares comes ahead of submission to regulators for approval of drug for rare condition
Results are a record for Dublin-based company, which has recently listed on Nasdaq
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices